anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a cell adhesion inhibitor containing a 2-amino-3-halogeno-1,4- naphthoquinone derivative. CONSTITUTION: This medicine contains a compound of the formula (R<1> and R<2> are each H or OH; R<3> is a lower alkyl, a 3-7C cycloalkyl, acryl, etc.; R<4> is H, etc.; X is a halogen) or its salt as an active ingredient. The compound of the formula has inhibitory action on adhesion of leukocyte and cancerous cell to hemangioendothelial cell and is useful for and antiinflammatory medicine, a therapeutic agent for ischemic re-perfusion disorder, an inhibitor for organ transplantation rejection and a therapeutic agent for autoimmune diseases and an inhibitor for tumor metastasis and has an action mechanism different from that in current clinic use.  The daily dose is 10mg-1g per adult in the case of an antiinflammatory medicine, 0.01-10mg in the case of a therapeutic agent for ischemic re-perfusion disorder, 1mg to 1g in the case of an inhibitor for organ transplantation rejection, 0.01-100mg in the case of a therapheutic agent for autoimmune diseases, and 0.1-100mg once to several times daily via oral or parenteral route in the case of an inhibitor for tumor metastasis.
This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist.
A solid mixture of a degradable polymer (B) in which an active agent loaded microporous powder or granulate form polymer (A) is uniformly dispersed. The active agent loaded polymer (A) is distributed throughout said polymer matrix by simple stirring of polymer (A) in a melt of polymer (B) or through kneading of polymer (A) and (B) or through coextrusion of polymers (A) and (B). The preparation of powder or granulate form structures and of shaped solid structures is possible according to the invention. The speed of degradation of polymer (B) in the selected surrounding environment, for instance, a human or animal body, determines the release rate of the active agent so that the release takes place in accordance with a velocity rule zero arrangement and is a constant or invariable. In this manner the release of the active agent into the surrounding environment or mileau is controlled and maintained according to predetermined conditions. The solid structures of the invention are suitable for the release of solid and liquid active agents such as medicaments, hormones, fertilizers, pesiticides and the like. Preferably, the polymers used are based on polylactides.
Background and Objectives: Cardiovascular events are the major cause of morbidity and mortality in patients on hemodialysis (HD). Identifying risk factors can help in the effort to reduce cardiovascular risk and improve life expectancy. The objective of this study was to evaluate the ability of the CHA2DS2-VASc score-the risk index of stroke in atrial fibrillation (AF)-to predict strokes, major cardiovascular events, and mortality in patients with end-stage kidney disease. Materials and Methods: The CHA2DS2-VASc and HAS-BLED scores (the bleeding risk from the use of anticoagulation in AF) were calculated in 237 HD patients, 99 women with a median age of 76 (15) years, at the time they commenced HD. The scores' ability to predict long term cardiovascular morbidity and mortality was estimated, both in those with and without AF. Among the exclusion criteria were the change of dialysis method or loss of follow-up, HD due to acute renal failure, and incompliance with medical instructions, thus the sample is not representative of a broader population. Results: The CHA2DS2-VASc score was higher in AF (n = 69) compared to non-AF (n = 168) patients, 5 (2.5) vs. 4 (2), p < 0.0001, respectively. An increased CHA2DS2-VASc score was correlated with cardiovascular events, namely, heart failure (p = 0.007, p = 0.024), stroke (p < 0.0001, p < 0.0001), and risk of all-cause mortality (p < 0.0001, p < 0.0001) in AF and non-AF groups, respectively. The C statistics indicated that the referred score showed modest discrimination in AF and non-AF patients on HD for heart failure, stroke, and all-cause mortality, however for cardiovascular mortality this was found only in the AF group. Conclusions: An increased CHA2DS2-VASc score at the time of HD initiation can predict strokes, heart failure, and all-cause mortality in HD patients independent of the presence of AF. The risk of cardiovascular mortality could only be predicted in patients with AF.
The invention relates to a nymphaea-tetragona anthocyanidin antioxidative face-pasted mask which is used for anti-oxidation intensive nursing of skin. Free radical is activated because of air pollution, ultraviolet ray, adhesion of color cosmetics, and other factors, and skin is attacked by the free radical. Compared with a smearing type mask, the face-pasted mask has the characteristics of being convenient to use and easy to clean, and is capable of deep going into skin corium layer to resist free radical. Most of compositions of anti-oxidation products currently on the market are VE, VC and OPC in grape seeds, and the product employing nymphaea-tetragona anthocyanidin almost is blank in the market. The invention aims at providing the face-pasted mask which employs nymphaea-tetragona anthocyanidin as the main anti-oxidation composition, utilizes natural chitosan as a matrix of the face-pasted mask, employs natural prunus dulcus oil as base oil of liquid essence, employs an anticorrosion composition natural antiseptic coming from marine organisms, and utilizes natural citric acid as an acid-base adjusting agent. The pH value of the face-pasted mask is adjusted to be weak acidity suitable for skin, and the face-pasted mask is natural, organic and purely biological, good in antioxidation efficacy, light, thin and air permeable.
Nutrition has been increasingly recognized for its use in mental health. Depression is commonly observed in patients with chronic liver disease (CLD). Building on our recent findings of depression-like behaviors in mice with hepatic ischemia/reperfusion (HI/R) injury, mediated by the gut-liver-brain axis, this study explored the potential influence of dietary sulforaphane glucosinolate (SGS) on these behaviors. Behavioral assessments for depression-like behaviors were conducted 7 days post either sham or HI/R injury surgery. Dietary intake of SGS significantly prevented splenomegaly, systemic inflammation, depression-like behaviors, and downregulation of synaptic proteins in the prefrontal cortex (PFC) of HI/R-injured mice. Through 16S rRNA analysis and untargeted metabolomic analyses, distinct bacterial profiles and metabolites were identified between control + HI/R group and SGS + HI/R group. Correlations were observed between the relative abundance of gut microbiota and both behavioral outcomes and blood metabolites. These findings suggest that SGS intake could mitigate depression-like phenotypes in mice with HI/R injury, potentially through the gut-liver-brain axis. Additionally, SGS, found in crucial vegetables like broccoli, could offer prophylactic nutritional benefits for depression in patients with CLD.
The invention relates to medicine for treating stomach flatulence. The medicine is prepared from, by weight, 6 parts of radix angelica sinensis, 9 parts of toosendan fruits, 10 g of corallodiscus flabellatus, 10 parts of semen brassicae, 8 parts of viola verecunda A. Gray, 6 parts of entireleaf neoalsomitra, 15 parts of semen agriophylli squarrosi, 10 parts of thunbergia fragrans, 6 parts of adenophora trachelioides maxim. and 1.5 parts of benzoin. According to the medicine, the radix angelica sinensis nourishes the liver, invigorates the circulation of blood and has a circulation property; the toosendan fruits relieve the liver for smoothing Qi; the corallodiscus flabellatus replenishes qi to invigorate the spleen and warms yang for dispelling cold; the semen brassicae tonifies qi to relieve pain and warms the spleen and the stomach for dispelling cold; the viola verecunda A. Gray tonifies the five internal organs, supplements qi and blood, relieves five consumptions and tonifies qi; the entireleaf neoalsomitra clears away heat and toxic materials and relieves pain; the semen agriophylli squarrosi tonifies the spleen and the stomach and helps digestion and regulates middle energizer; the thunbergia fragrans invigorates the stomach, helps digestion, resolves toxin and disperses swelling; the adenophora trachelioides maxim. moistens dryness and resolves phlegm; the benzoin induces resuscitation, refreshes the mind, clears phlegm, repels foulness, promotes qi to activate blood and relieves pain; all types of medicinal materials are combined and jointly achieve the effects of warming the spleen and the stomach, tonifying the spleen, nourishing yin and tonifying the stomach, smoothing the liver and regulating qi, and harmonizing the stomach and relieving depression. It is proved by clinical experiments that stomach flatulence can be treated safely and effectively.
Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
Do not chew tablets or swallow them whole.

Take Exjade once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day. Completely disperse tablets by stirring in water, orange juice, or apple juice until a fine suspension is obtained. Disperse doses of less than 1 g in 3.5 ounces of liquid and doses of 1 g or greater in 7 ounces of liquid. After swallowing the suspension, resuspend any residue in a small volume of liquid and swallow. Do not take Exjade with aluminum-containing antacid products [see Drug Interactions (7.1)].
After enrollment, subjects' previous tumor block used for glioblastoma diagnosis that is consented to provide during the study period will be sent to a central laboratory for the assessment of MGMT status. Moreover, subjects will be randomized in either Control or Study arm at Visit 2. Subjects in Control arm will receive a standard chemoradiation. However, subjects in Study arm will receive a standard chemoradiation in combination with concurrent JP001 in whole study period. During the study, a sufficient amount of investigational products will be supplied to subjects in study groups until next scheduled visits. Subjects will self-administer investigational product orally with water at approximately the same time in each day. Subjects should fast for a minimum of 2 hours prior to any doses of JP001 and/or Temozolomide and then fast for another 1 hour after taking JP001 and/or Temozolomide. During and at the end of treatment, subjects will be evaluated for efficacy and safety parameters. Moreover, there will be a Follow-up visit for safety 4 weeks after the End-of-Treatment visit. If a subject is early withdrawn from the study, the End-of-Treatment visit should be arranged and all assessments assigned in this visit should be performed. The Safety Follow-up visit for early withdrawn subjects could be either clinic visit or telephone contact. If withdrawn subjects refuse to perform Follow-up visit, the Follow-up visit is allowed to cancel. For subjects who completed or discontinued study treatment, assessment of survival status will be performed every 8 weeks by telephone contact until death, study end (last subject last visit; the last subject needs to be followed at least 30 months), or study termination by Sponsor. Survival information will be recorded in the medical source and CRF. If subjects are lost to follow-up or refuse to receive the assessment of survival status, the investigator will record the last date subjects known to be alive in the medical source and case report form.
FIELD: veterinary microbiology, biotechnology. SUBSTANCE: strain Streptococcus zooepidemicus VGNKI N K-DEP is cultured on beef-extract broth with 1% glucose solution at 37-38 C for 18-24 h. To this time concentration of bacterial mass must be 4 x 10 9 mk/1 ml, not less. The grown culture is inactivated with 0.3% formalin solution. After inactivation sterile adjuvant (3% solution of aluminium hydroxide) is added to bacterial mass. The obtained formol-aluminium hydroxide vaccine provides the formation of stable lasting immunity. Epizootic effectiveness of vaccine is up to 85.4% of all infected animals. EFFECT: enhanced effectiveness of vaccine. 1 tbl
Residual neoplasia after EMR is a common. Optimal surveillance protocols are not clearly defined. There is a need for better imaging modalities to evaluate for residual disease. Suspected residual tissue can be confirmed with repeat colonoscopy or can be empirically treated. However, this can lead to either frequent colonoscopy or overtreatment. This presents more cost and financial burden to the patient. With the introduction of newer colonoscopes that have near focus/zoom capability, it is important to assess whether the near focus technology offers better accuracy for detection of residual neoplastic tissue. With better accuracy to confidently rule out residual neoplasia using newer imaging modality, additional treatment or biopsy at the previous EMR may be avoided. Furthermore, the interval for surveillance colonoscopy can be lengthened.
Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
FIELD: medicine, organic chemistry, biochemistry, peptides. SUBSTANCE: invention relates to synthesis of peptides. Invention claims the novel heptapeptide: lysyl-glutamyl-aspartyl-alanyl-prolyl-glycyl-proline of the general formula: Lys-Glu-Asp-Ala-Pro-Gly-Pro eliciting stimulating and regulating effect on protein synthesis in hepatocytes. Proposed heptapeptide shows ability to effect biochemical parameters in function of endogenous opioid system. Heptapeptide doesn't elicit psychotropic effect and doesn't affect psychomotor activity of animals in used behavioral tests. Proposed heptapeptide can be used as a base for development of medicinal forms eliciting hepatoprotective activity. EFFECT: valuable medicinal and biochemical properties of peptide. 1 dwg, 4 tbl, 3 ex
Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2 H -1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its molecular formula is C 7 H 8 CIN 3 O 4 S 2 and its structural formula is: 

It is a white, or practically white, crystalline powder with a molecular weight of 297.74 which is slightly soluble in water, freely soluble in sodium hydroxide solution, in n-butylamine and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform and in dilute mineral acids.

Each tablet for oral administration contains 25 mg and 50 mg of hydrochlorothiazide respectively. In addition, each tablet contains following inactive ingredients: anhydrous lactose, D&C Yellow No.10 aluminum lake, FD&C Red No. 40 aluminum lake, magnesium stearate, pregelatinized starch and sodium starch glycolate.
PURPOSE OF REVIEW: Mirogabalin is a novel gabapentinoid medication for the treatment of neuropathic pain. The purpose of this review is to discuss current evidence for its use. Gabapentinoids are widely prescribed for neuropathic pain. Mirogabalin offers theoretical advantages over traditional gabapentinoids due to its specificity for the α2δ-1 subunit of voltage-gated calcium channels. It is theorised that this specificity may reduce adverse drug reactions by minimising binding to the α2δ-2 subunit which is responsible for many of the gabapentinoid side effects.
RECENT FINDINGS: Mirogabalin's slower dissociation from the α2δ-1 compared with α2δ-2, and its higher potency may also impart an efficacy benefit over traditional gabapentinoids. These theoretical advantages of mirogabalin remain inconclusive in clinical practice, with mixed evidence regarding mirogabalin versus traditional gabapentinoids. Some studies suggest a reduced side effect profile yet, others fail to demonstrate significant differences. Regarding efficacy, mirogabalin may be superior to placebo for several neuropathic pain syndromes, but evidence of widespread benefit over traditional gabapentinoids is currently lacking.
SUMMARY: Mirogabalin offers theoretical promise, but large, independent studies are required to further assess its performance versus traditional gabapentinoids.
Combination of plant extracts under liquid form. Oral administration. Dosage 100 ml. To drink 1h00 before alcohol intake together with meal.
The present invention provides for identification of agents that induce growth arrest and survival of cancer cells, which remain dormant in bone marrow, thus preventing their eradication through use of standard chemotherapy or radiation therapy. Basic fibroblast growth factor (FGF-2), a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively differentiated breast cancer cells and restricts their survival to fibronectin by upregulating integrin α5β1. Most of the FGF-2-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Using function-blocking antibodies and peptides, a specific contribution of α5β1-fibronectin interaction in maintaining survival of growth-arrested cells was demonstrated. The present invention thus allows for methods, agents and pharmaceutical compositions that can be used to potentiate the activity of chemotherapy or radiation therapy.
Increases in the rates of childhood ADHD over the past two decades have lead to speculation that calcitriol deficiency (e.g., secondary to the increased use of sunscreen and/or increases in sedentary, indoor lifestyles in children) plays a causal/contributory role in the etiology of ADHD. To date, evidence of a direct link is lacking. One study showed higher maternal circulating Vitamin D levels in pregnancy are associated with lower risk of developing ADHD-like symptoms in childhood. On the other hand, another study did not replicate the above association, and a prospective study using umbilical cord samples stored at the time of birth reported no difference in serum vitamin D levels between ADHD group versus healthy controls. In terms of clinical trials, one randomized double blind study among adults with ADHD reported a beneficial effect of the intervention, measured with the Conners Adult ADHR rating scale, in comparison with placebo, but the intervention included the combination of vitamin D and several other micronutrients. An analysis of moderators of a positive response to ADHD behaviors did not reveal a significant predictive effect of vitamin D.

However, recent studies provide intriguing indirect evidence of an inverse relationship between solar intensity (SI) and/or altitude (a proxy for greater sun/UV light exposure) and regional rates of ADHD. One study examined three large datasets across 49 U.S. states for 2003 and 2007, and across 9 non-U.S. countries. This study examined the prevalence of ADHD and Solar Intensity (SI) maps. They found an inverse association between solar intensity and prevalence of ADHD. Another study examined two national survey datasets. They found an inverse relationship between altitude and prevalence of ADHD. Investigators hypothesize, as suggested by Huber, that a common denominator on the above studies is the increased vitamin D levels in those exposed to a higher solar intensity, which is known to increase with altitude.
BACKGROUND: In prior research employing iTRAQ (Isobaric Tags for Relative and Absolute Quantitation) technology, we identified a range of proteins in breast cancer tissues exhibiting high levels of acetylation. Despite this advancement, the specific functions and implications of these acetylated proteins in the context of cancer biology have yet to be elucidated. This study aims to systematically investigate the functional roles of these acetylated proteins with the objective of identifying potential therapeutic targets within breast cancer pathophysiology.
METHODS: Acetylated targets were identified through bioinformatics, with their expression and acetylation subsequently confirmed. Proteomic analysis and validation studies identified potential acetyltransferases and deacetylases. We evaluated metabolic functions via assays for catalytic activity, glucose consumption, ATP levels, and lactate production. Cell proliferation and metastasis were assessed through viability, cycle analysis, clonogenic assays, PCNA uptake, wound healing, Transwell assays, and MMP/EMT marker detection.
RESULTS: Acetylated proteins in breast cancer were primarily involved in metabolism, significantly impacting glycolysis and the tricarboxylic acid cycle. Notably, PGK1 showed the highest acetylation at lysine 323 and exhibited increased expression and acetylation across breast cancer tissues, particularly in T47D and MCF-7 cells. Notably, 18 varieties acetyltransferases or deacetylases were identified in T47D cells, among which p300 and Sirtuin3 were validated for their interaction with PGK1. Acetylation at 323 K enhanced PGK1's metabolic role by boosting its activity, glucose uptake, ATP production, and lactate output. This modification also promoted cell proliferation, as evidenced by increased viability, S phase ratio, clonality, and PCNA levels. Furthermore, PGK1-323 K acetylation facilitated metastasis, improving wound healing, cell invasion, and upregulating MMP2, MMP9, N-cadherin, and Vimentin while downregulating E-cadherin.
CONCLUSION: PGK1-323 K acetylation was significantly elevated in T47D and MCF-7 luminal A breast cancer cells and this acetylation could be regulated by p300 and Sirtuin3. PGK1-323 K acetylation promoted cell glycolysis, proliferation, and metastasis, highlighting novel epigenetic targets for breast cancer therapy.